Used in cancer immunotherapy to target dendritic cells and enhance antigen presentation, promoting strong T-cell immune responses against tumor cells. Specifically investigated in clinical trials for cancers such as melanoma and ovarian cancer, often in combination with immune-stimulating agents to improve efficacy. Its ability to bind LY75 (CD205), a receptor highly expressed on dendritic cells, enables targeted delivery of tumor antigens, making it a valuable tool in vaccine-based therapies and adoptive immune treatments.